Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

NCT05152472 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT05152472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05152472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Recruiting
Start date
January 14, 2022
Completion date
October 31, 2027
Enrollment
110 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastrointestinal stromal tumor (gist), metastatic gastrointestinal stromal tumor, unresectable gastrointestinal stromal tumor (gist)